What is HC Wainwright’s Forecast for PVLA Q1 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Palvella Therapeutics in a research report issued on Wednesday, April 1st. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.89) for the quarter. HC Wainwright has a “Buy” rating and a $270.00 price objective on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q2 2026 earnings at ($1.02) EPS, Q3 2026 earnings at ($1.19) EPS and Q4 2026 earnings at ($1.30) EPS.

Other equities research analysts have also issued research reports about the stock. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. BTIG Research boosted their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Chardan Capital boosted their target price on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a research report on Tuesday. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Finally, Mizuho increased their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $198.07.

Palvella Therapeutics Price Performance

Shares of Palvella Therapeutics stock opened at $120.38 on Thursday. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $151.18. The firm’s 50-day moving average is $105.80 and its two-hundred day moving average is $91.85. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -32.45 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Tuesday, March 31st. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13).

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, Director Elaine J. Heron acquired 2,400 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the transaction, the director owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. The trade was a 5.28% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The SEC filing for this sale provides additional information. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

Hedge funds have recently modified their holdings of the stock. Group One Trading LLC raised its position in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Palvella Therapeutics by 11.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after buying an additional 433 shares during the period. Archer Investment Corp purchased a new stake in shares of Palvella Therapeutics during the 3rd quarter worth $28,000. Bank of America Corp DE increased its holdings in Palvella Therapeutics by 12.3% in the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after buying an additional 515 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Palvella Therapeutics by 8.7% during the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock worth $690,000 after purchasing an additional 528 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.